Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Richard F. O'Brien is active.

Publication


Featured researches published by Richard F. O'Brien.


Journal of Cardiovascular Pharmacology | 1992

Endothelin-1 increases the pulmonary microvascular pressure and causes pulmonary edema in salt solution but not blood-perfused rat lungs.

David M. Rodman; Thomas J. Stelzner; Martin R. Zamora; Scott T. Bonvallet; Masahiko Oka; Katzuhiko Sato; Richard F. O'Brien; Ivan F. McMurtry

Summary: Endothelin-1 (ET-1) is a potent vasoactive peptide that has been reported to cause lung edema. This study tested if the edemagenic effect of ET-1 is due to preferential venoconstriction and, if so, whether the site of resistance is similar with salt solution (PSS) and more physiologic blood perfusate. ET-1 caused concentration-dependent contraction of pulmonary arterial and venous rings, with an EC50 of 1.3 nM in artery and 0.6 nM in vein (p < 0.05). In PSS-perfused lungs, 5 nM ET-1 caused a 7.0 ± 0.8 torr pressor response that was associated with a 5.0 ± 0.3 torr increase in microvascular pressure and a 530 ± 20 mg increase in lung weight within 10 min. In contrast, KCl-treated lungs had an equivalent pressor response (7.4 ±1.1 torr), yet the microvascular pressure increased by only 2.5 ± 0.4 torr (p < 0.05 from ET-1) and the lung weight was unchanged. Meclofenamate did not prevent the effect of ET-1 on microvascular pressure or lung weight. In blood-perfused lungs, ET-1 caused a 7.3 ± 0.1 torr pressor response but only a 2.0 ± 0.5 torr increase in microvascular pressure and no increase in lung weight. ET-1 had no effect on permeability either of cultured endothelial cell monolayers or in the pulmonary microvasculature in vivo. We conclude that the edemagenic effect of ET-1 in PSS-perfused lungs is mediated through venoconstriction and an increase in microvascular pressure. The physiological significance of this increase is uncertain, as blood perfusate appears to shift the principal site of vasoconstriction from post- to precapillary vessels, thus preventing the increase in microvascular pressure and edema.


Experimental Lung Research | 1985

Studies on the Mechanism of Decreased Angiotensin I Conversion in Rat Lungs Injured with Alpha-Naphthylthiourea

Richard F. O'Brien; Joseph S. Makarski; Sharon Rounds

Lung endothelial cell injury may be an important early event in the pathogenesis of increased permeability pulmonary edema. Since angiotensin converting enzyme (ACE) is located on the luminal surface of the endothelial cell membrane, we sought to determine whether the conversion of angiotensin I (AI) to angiotensin II is decreased after acute lung injury to rats, induced by alpha-naphthylthiourea (ANTU), and we investigated the mechanism of the decrease. We found that lungs isolated from rats treated 4 h earlier with ANTU at a dose of 15 mg/kg body weight (BW) had decreased AI conversion when perfused with Krebs-Henseleit at a constant flow rate of 30 ml/min/kg BW. When perfusate flow rate was increased from 30 to 50 ml/min/kg BW, lungs isolated from rats treated with 10 mg/kg BW ANTU also had decreased AI conversion when compared to controls treated with a vehicle, Tween 80. Investigating the mechanism of decreased AI conversion, there were no differences among experimental groups in pulmonary arterial pressures or effluent perfusate pH or pO2. There was no correlation between lung wet/dry weight ratios and the extent of AI conversion among control rat lungs. Lung homogenate and serum ACE activity did not differ among control rats and rats pretreated with the two doses of ANTU. Ultrastructural studies revealed an increased percentage of capillaries with blebbing of endothelial cells in lungs injured with ANTU, as compared to controls, but no evidence of increased endothelial cell denudation in injured lungs. We conclude that angiotensin I conversion is decreased after ANTU lung injury and that the extent of decrease is related to the dose of ANTU and to perfusate flow rate. Although we cannot exclude decreased vascular surface area perfused as a cause of decreased conversion, we speculate that subtle changes in the luminal endothelial cell membrane may have caused decreased AI conversion after ANTU lung injury.


The American review of respiratory disease | 1990

Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacteria

Richard J. Wallace; Richard F. O'Brien; Jeffrey Glassroth; James W. Raleigh; Asim K. Dutt


The American review of respiratory disease | 1992

Factors Influencing the Idiopathic Development of Pulmonary Hypertension in the Fawn Hooded Rat

Kazuhiko Sato; Sally Webb; Alan Tucker; Marlene Rabinovitch; Richard F. O'Brien; Ivan F. McMurtry; Thomas J. Stelzner


Clinical Infectious Diseases | 1992

Tsukamurella paurometabolum: A Novel Pathogen Causing Catheter-Related Bacteremia in Patients with Cancer

Charles L. Shapiro; Rachel F. Haft; Nelson M. Gantz; Gary V. Doern; John C. Christenson; Richard F. O'Brien; James C. Overall; Barbara A. Brown; Richard J. Wallace


The American review of respiratory disease | 1984

Thiourea causes endothelial cells in tissue culture to produce neutrophil chemoattractant activity

Richard F. O'Brien; Margaret P. Seton; Joseph S. Makarski; Sharon Rounds


Chest | 1989

Diagnosis of Pneumocystis carinii Pneumonia by Induced Sputum in a City with Moderate Incidence of AIDS

Richard F. O'Brien; Janet L. Quinn; Ben T. Miyahara; Ronald B. Lepoff; David L. Cohn


The American review of respiratory disease | 1989

In Search of Shortcuts: Definitive and Indirect Tests in the Diagnosis of Pneumocystis carinii Pneumonia in AIDS

Richard F. O'Brien


Clinical Infectious Diseases | 1992

Evaluation of New Anti-Infective Drugs for the Treatment and Prevention of Tuberculosis

Philip C. Hopewell; Michael H. Cynamon; Jeffrey R. Starke; Michael D. Iseman; Richard F. O'Brien


Chest | 1988

Pulmonary Vascular Reactivity

Ivan F. McMurtry; David M. Rodman; Takashi Yamaguchi; Richard F. O'Brien

Collaboration


Dive into the Richard F. O'Brien's collaboration.

Top Co-Authors

Avatar

Jeffrey R. Starke

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Michael D. Iseman

University of Colorado Denver

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ivan F. McMurtry

University of South Alabama

View shared research outputs
Top Co-Authors

Avatar

David M. Rodman

University of Colorado Denver

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Richard J. Wallace

University of Texas Health Science Center at Tyler

View shared research outputs
Researchain Logo
Decentralizing Knowledge